South Korea's SillaJen, which has ambitions to launch its oncolytic virus-based immunotherapy Pexa-Vec in global markets in the next few years, has unveiled progress of its global Phase III study and the company's global strategy during the recent BIO Korea 2016 in Seoul.
SEOUL - SillaJen Inc., which has just begun a global Phase III study of its oncolytic virus-based immunotherapy Pexa-Vec for hepatocellular carcinoma (HCC), aims to retain rights in some regions until as late as possible in order to maximize the value of the project.
Pexa-Vec (JX-594, pexastimogene devacirepvec) is the most advanced product candidate from the private South Korean clinical-stage biotherapeutics firm’s proprietary SOLVE (Selective Oncolytic Vaccinia Engineering) platform
Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.
Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.
InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.
Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.
The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.
The details of Trump’s latest executive order on drug pricing are vague and the president put more blame on other countries and pharma distributors than drug companies.
Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.
